These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20722561)

  • 1. Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy.
    Aggarwal HK; Jain D; Talapatra P; Yadav RK; Gupta T; Kathuria KL
    Ren Fail; 2010; 32(8):941-6. PubMed ID: 20722561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxycycline: a pilot study to reduce diabetic proteinuria.
    Naini AE; Harandi AA; Moghtaderi J; Bastani B; Amiran A
    Am J Nephrol; 2007; 27(3):269-73. PubMed ID: 17429196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    J Nephrol; 2007; 20(4):410-6. PubMed ID: 17879206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P; Eiam-Ong S; Suwanwalaikorn S
    J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
    Navarro JF; Mora C; Muros M; García J
    J Am Soc Nephrol; 2005 Jul; 16(7):2119-26. PubMed ID: 15917336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy.
    Roozbeh J; Banihashemi MA; Ghezlou M; Afshariani R; Salari S; Moini M; Sagheb MM
    Ren Fail; 2010 Jan; 32(2):172-8. PubMed ID: 20199178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
    Rasi Hashemi S; Noshad H; Tabrizi A; Mobasseri M; Tayebi Khosroshahi H; Heydarnejad M; Khalaj MR; Aghamohammadzadeh N
    Iran J Kidney Dis; 2012 Jan; 6(1):39-43. PubMed ID: 22218118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan.
    Yeh HL; Huang LY; Su S; Yang MC; Wang TC
    Health Policy; 2011 May; 100(2-3):196-202. PubMed ID: 21146895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lack of effect of ACE inhibition on severe proteinuria in diabetic nephropathy--a 6-month-long study].
    Hay U; Ludvik B; Gisinger C; Schernthaner G
    Schweiz Med Wochenschr; 1988 Feb; 118(5):165-9. PubMed ID: 3278375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
    Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
    Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria.
    Lubrano R; Soscia F; Elli M; Ventriglia F; Raggi C; Travasso E; Scateni S; Di Maio V; Versacci P; Masciangelo R; Romero S
    Pediatrics; 2006 Sep; 118(3):e833-8. PubMed ID: 16923922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A; Hayashi K; Saruta T
    Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.